Advisory Board November 19, 2025

FDA has launched a new “plausible mechanism pathway” to help expedite approvals of personalized treatments for rare diseases, in today’s bite-sized hospital and health industry news from the District of Columbia, Maryland, and Washington.

  • District of Columbia: Ann Mond Johnson, CEO of the American Telemedicine Association (ATA), will retire from her position, effective Dec. 10. Mond Johnson first joined ATA in 2018, and she led the organization through the COVID-19 pandemic, when telehealth use increased dramatically. “It has been a remarkable journey and privilege to guide the work of the ATA through this transformative period. I am proud of our incredible accomplishments, especially our work creating actionable tools to help organizations improve access to needed care, and the...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies
Related Articles:
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1)

Share Article